CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Download this short summary slideset of key takeaway points from a live presentation on integrating CAR T-cell therapy into management of patients with hematologic malignancies.

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

Download these slides from our live meeting series to review key strategies for integrating CAR T-cell therapy into your management of patients with hematologic malignancies.

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.

Jeremy S. Abramson, MD, MMSc Released: March 12, 2021

Listen to Noopur Raje, MD, answer audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.

Noopur Raje, MD Released: March 12, 2021

Download this slideset for key insights from our podcast featuring expert answers to questions on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.

Noopur Raje, MD Released: March 12, 2021

Listen to Frederick L. Locke, MD, answer audience questions from a live CCO Webinar focused on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.

Frederick L. Locke, MD Released: March 18, 2021

In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.

Renier J. Brentjens, MD, PhD
Program Director Frederick L. Locke, MD Noopur Raje, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: March 29, 2021 Expired: March 28, 2022